Physician profile
Carrie E Marlow
NPI 1215241294
$2,891.63
in general payments reported to CMS, 2019-2025
15 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $1,093 · 2023: $524 · 2024: $260 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $550.22 | 2021-2025 | Jardiance |
| Amgen INC. | $470.01 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $461.59 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $330.37 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $265.74 | 2021-2024 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $254.10 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $139.70 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $100.93 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $80.13 | 2022-2024 | |
| Abbott Laboratories | $64.14 | 2021-2022 | |
| Bridgebio Pharma, INC. | $62.66 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $44.62 | 2024 | Arcalyst |
| Pfizer INC. | $28.76 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.12 | 2023 | Lifevest |
| Medtronic, INC. | $16.54 | 2023 | Micra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Marlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.